120 related articles for article (PubMed ID: 21317741)
1. A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed.
D'Angelo SP; Kris MG; Pietanza MC; Rizvi NA; Azzoli CG
J Thorac Oncol; 2011 Mar; 6(3):624-6. PubMed ID: 21317741
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed-induced edema of the eyelid.
Kurata T; Tamura K; Okamoto I; Satoh T; Nakagawa K; Fukuoka M
Lung Cancer; 2006 Nov; 54(2):241-2. PubMed ID: 16996165
[TBL] [Abstract][Full Text] [Related]
3. Pemetrexed-induced cellulitis: a rare toxicity in non-small cell lung cancer treatment.
Katsenos S; Psara A; Panagou C
J Oncol Pharm Pract; 2013 Mar; 19(1):93-4. PubMed ID: 22357637
[TBL] [Abstract][Full Text] [Related]
4. Pemetrexed-induced eyelid edema in lung cancer.
Martins-Filho PR; Kameo SY; Mascarenhas-Oliveira AC; Vieira NF; Azevedo E
J Craniofac Surg; 2013 Jul; 24(4):e401-3. PubMed ID: 23851735
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of pemetrexed in chemotherapy-naive elderly patients aged ≥ 75 years with advanced non-squamous non-small-cell lung cancer (HANSHIN Oncology Group 003).
Hattori Y; Iwasaku M; Satouchi M; Nishiyama A; Korogi Y; Otsuka K; Fujita S; Katakami N; Mori M; Nishino K; Morita S; Negoro S
Jpn J Clin Oncol; 2013 Dec; 43(12):1184-9. PubMed ID: 24168805
[TBL] [Abstract][Full Text] [Related]
6. A case of pemetrexed-induced acute lung injury in non-small cell lung cancer.
Kim HO; Lee SY; Shim JJ; Kang KH; Shin BK
J Thorac Oncol; 2010 Mar; 5(3):401-2. PubMed ID: 20186027
[No Abstract] [Full Text] [Related]
7. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
Li N; Ou W; Yang H; Liu QW; Zhang SL; Wang BX; Wang SY
Cancer; 2014 May; 120(9):1379-86. PubMed ID: 24481719
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
Mita AC; Sweeney CJ; Baker SD; Goetz A; Hammond LA; Patnaik A; Tolcher AW; Villalona-Calero M; Sandler A; Chaudhuri T; Molpus K; Latz JE; Simms L; Chaudhary AK; Johnson RD; Rowinsky EK; Takimoto CH
J Clin Oncol; 2006 Feb; 24(4):552-62. PubMed ID: 16391300
[TBL] [Abstract][Full Text] [Related]
9. Skin toxicities compromise prolonged pemetrexed treatment.
Eguia B; Ruppert AM; Fillon J; Lavolé A; Gounant V; Epaud C; Milleron B; Moguelet P; Wislez M; Frances C; Cadranel J
J Thorac Oncol; 2011 Dec; 6(12):2083-9. PubMed ID: 21892100
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer.
Takeoka H; Yamada K; Azuma K; Zaizen Y; Yamashita F; Yoshida T; Naito Y; Okayama Y; Miyamoto M; Hoshino T
Jpn J Clin Oncol; 2014 May; 44(5):472-8. PubMed ID: 24688087
[TBL] [Abstract][Full Text] [Related]
11. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
[TBL] [Abstract][Full Text] [Related]
12. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Paz-Ares LG; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
J Clin Oncol; 2013 Aug; 31(23):2895-902. PubMed ID: 23835707
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study.
Zhang DS; Jin Y; Luo HY; Wang ZQ; Qiu MZ; Wang FH; Li YH; Xu RH
Br J Cancer; 2015 Jan; 112(2):266-70. PubMed ID: 25474247
[TBL] [Abstract][Full Text] [Related]
14. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.
Belani CP; Brodowicz T; Ciuleanu TE; Krzakowski M; Yang SH; Franke F; Cucevic B; Madhavan J; Santoro A; Ramlau R; Liepa AM; Visseren-Grul C; Peterson P; John WJ; Zielinski CC
Lancet Oncol; 2012 Mar; 13(3):292-9. PubMed ID: 22336221
[TBL] [Abstract][Full Text] [Related]
15. Alveolar hemorrhage associated with pemetrexed administration.
Kurimoto R; Sekine I; Iwasawa S; Sakaida E; Tada Y; Tatsumi K; Takahashi Y; Nakatani Y; Imai C; Takiguchi Y
Intern Med; 2015; 54(7):833-6. PubMed ID: 25832952
[TBL] [Abstract][Full Text] [Related]
16. Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma.
Huang XE; Tian GY; Cao J; Xu X; Lu YY; Wu XY; Liu J; Shi L; Xiang J
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6663-7. PubMed ID: 24377585
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.
Kim YH; Hirabayashi M; Kosaka S; Nikaidoh J; Yamamoto Y; Shimada M; Toyazaki T; Nagai H; Sakamori Y; Mishima M
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1445-51. PubMed ID: 23532206
[TBL] [Abstract][Full Text] [Related]
18. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Pujol JL; Paz-Ares L; de Marinis F; Dediu M; Thomas M; Bidoli P; Corral J; San Antonio B; Chouaki N; John W; Zimmermann A; Visseren-Grul C; Gridelli C
Clin Lung Cancer; 2014 Nov; 15(6):418-25. PubMed ID: 25104617
[TBL] [Abstract][Full Text] [Related]
19. Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study.
Gridelli C; de Marinis F; Thomas M; Prabhash K; El Kouri C; Blackhall F; Bustin F; Pujol JL; John WJ; San Antonio B; Zimmermann A; Chouaki N; Visseren-Grul C; Paz-Ares LG
J Thorac Oncol; 2014 Jul; 9(7):991-997. PubMed ID: 24926544
[TBL] [Abstract][Full Text] [Related]
20. [Safety of pemetrexed according to the duration of vitamin B12 and folic acid supplementation prior to the first dose of pemetrexed].
Tsuda Y; Kitamura A; Nishimura N; Yagi N; Takayama S; Okafuji K; Tomishima Y; Jinta T; Koyama K; Ohde S; Gotoh K; Chohnabayashi N
Gan To Kagaku Ryoho; 2015 Apr; 42(4):471-5. PubMed ID: 25963695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
